



Willcox, A., Culliford, L., Ellis, L., Rogers, C. A., Cree, A., Chakravarthy, U., Ennis, S., Behar-Cohen, F., Reeves, B. C., Sivaprasad, S., & Lotery, A. (2019). Clinical efficacy of eplerenone versus placebo for central serous chorioretinopathy: study protocol for the VICI randomised controlled trial. *Eye*, 33(2), 295-303.
<https://doi.org/10.1038/s41433-018-0212-2>

Peer reviewed version

Link to published version (if available):
[10.1038/s41433-018-0212-2](https://doi.org/10.1038/s41433-018-0212-2)

[Link to publication record in Explore Bristol Research](#)
PDF-document

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

Supplementary information 2.

Concomitant medications which preclude inclusion in the VICI trial.

- Potassium-sparing diuretics.
- Potassium-supplements.
- Inhibitors of CYP 3A4 (e.g. amiodarone, diltiazem, fluconazole, itraconazole, ketoconazole, ritonavir, nelfinavir, saquinavir, clarithromycin, telithromycin, erythromycin, verapamil, spironolactone and nefazodone). *Note. Patients taking furosemide are eligible.*
- Nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g. ibuprofen, naproxen).
- Combination of an angiotensin converting enzyme (ACE) inhibitor and an angiotensin receptor blocker (ARB).
- Lithium, cyclosporine or tacrolimus.